NASDAQ · CRBU
Caribou Biosciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CRBU: Nov 11, 2026
Caribou Biosciences, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.27. The reported EPS for the same quarter last year was $-0.3.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.27 | $-0.25 | $-0.29 | 2 |
| Dec 2026 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Mar 2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Jun 2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · BNK Invest · Zacks · MarketBeat- RTTNews · Oct 9, 1:37 PM EDTWeekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) – This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.
- BNK Invest · Oct 8, 12:01 PM EDTThursday Sector Laggards: Biotechnology, Packaging & ContainersIn trading on Thursday, biotechnology shares were relative laggards, down on the day by about 2.4%. Helping drag down the group were shares of Caribou Biosciences, down about 19.3% and shares of Recursion Pharmaceuticals off about 9% on the day. Also lagging the market Thursda
- RTTNews · Oct 7, 1:48 AM EDTCaribou Biosciences To Halt Two CAR-T Programs, Cut Workforce; Shares Plunge(RTTNews) – Caribou Biosciences, Inc. (CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced plans to discontinue further development of its two allogeneic CAR-T cell therapy programs: vispa-cel for relapsed or refractory (r/r) B-cell non-Hodgkin lymp
- RTTNews · Oct 7, 12:57 AM EDTCaribou Begins Strategic Review & Plans To Halt CAR-T Programs; Stock Plunges(RTTNews) – On Tuesday, Caribou Biosciences, Inc. (CRBU) said it is exploring strategic alternatives to maximize stockholder value, including a potential merger, acquisition, business combination, or other strategic transactions involving the company or its assets.
- Zacks · Sep 14, 9:35 AM EDTCaribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for Caribou Biosciences (CRBU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversa
- Zacks · Aug 26, 11:17 AM EDTHere's Why You Should Retain IQVIA Stock in Your Portfolio NowIQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.
- Zacks · Aug 13, 6:05 PM EDTCaribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue EstimatesCaribou Biosciences (CRBU) delivered earnings and revenue surprises of +27.27% and -40.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 8:20 AM EDTIntellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue EstimatesIntellia Therapeutics (NTLA) delivered earnings and revenue surprises of 0.00% and -47.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 8:35 PM EDTVir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss EstimatesVir Biotechnology (VIR) delivered earnings and revenue surprises of -43.37% and -7.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 9, 9:40 AM EDTAre Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.
- MarketBeat · Jun 9, 6:04 AM EDTCaribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data NearsMarketBeat Week in Review – 7/10 – 7/14Caribou Biosciences (NASDAQ:CRBU) Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate vispa-cel now “pivotal-ready” and its multiple
- Fintel · May 14, 3:07 AM EDTCaribou Biosciences (CRBU) Price Target Increased by 38.57% to 12.37The average one-year price target for Caribou Biosciences (NasdaqGS:CRBU) has been revised to $12.37 / share. This is an increase of 38.57% from the prior estimate of $8.92 dated April 25, 2026. The price target is an average of many targets provided by analys
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Caribou Biosciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.